TID Issues COVID Guidance Update (August 20)

The Vaccine Section of the "Guidance on Coronavirus Disease 2019 (COVID-19) for Transplant Clinician" has been updated.


Read the latest Transplantation - Vol. 105, No. 9, September 2021

This issue includes data and analysis of the problem of COVID vaccination in the transplant population. Important data that will probably only be superseded by controlled clinical trials. The Notify project's first report on donor-derived disease. Liver transplantation data is focused on donor selection the early posttransplant period – extubation. The role of machine learning in donated kidney discard adds to the options to be considered to both improve our selection and increase utilization of the donor potential.

Online First Highlighted Article

Highlighted Tweet


IPTA 2022: Approaching Abstract Deadline

The PEDIATRIC transplant community is meeting IN PERSON in Prague!

Mark March 26-29, 2022 in your agenda.

View a special message from Dr. Carlos O. Esquival – IPTA President


Hot Off The Press

«HOT OFF THE PRESS» 
RECENT PUBLICATIONS IDENTIFIED
BY TTS EDUCATION COMMITTEE ON COVID-19

This week's selection made by Drs. Enver Akalin and Gabriel Gondolesi.

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

Victoria G. Hall et al.
New England Journal of Medicine; 2021 Aug 11. doi: 10.1056/NEJMc2111462. PMID: 34379917
120 Transplant recipientswithout previous history of COVID who had received two doses of mRNA-1273 were randomly assigned in a 1:1 ratio to receive either a third dose of mRNA-1273 vaccine or saline placebo 2 months after the second dose of mRNA-1273 (dosing schedule: 0, 1, and 3 months). At month 4, an anti-RBD antibody level of at least 100 U per milliliter was present in 33 of 60 patients (55%) in the mRNA-1273 group and in 10 of 57 patients (18%) in the placebo group (relative risk, 3.1; 95% confidence interval [CI], 1.7 to 5.8; P<0.001). After the third dose, the median percent virus neutralization was 71% in the mRNA-1273 group and 13% in the placebo group (95% CI for the between-group difference, 11 to 76 percentage points), and the percentage of patients above the 30% threshold for neutralizing antibody positivity was 60% and 25%, respectively (relative risk, 2.4; 95% CI, 1.5 to 4.0). Median severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific T-cell counts were greater after the third dose in the mRNA-1273 group than in the placebo group (432 vs. 67 cells per 106 CD4+ T cells; 95% CI for the between-group difference, 46 to 986). This study suggested that a third-dose booster Covid-19 vaccine should be considered, in conjunction with regulatory approval, for transplant recipients who have received two doses of mRNA-1273.

COVID-19-related medical research: a meta-research and critical appraisal

Marc Raynaud et al.
BMC Med Res Methodol. 2021 Jan 4;21(1):1. doi: 10.1186/s12874-020-01190-w. PMID: 33397292
Among the 11,452 publications identified, 10,516 met the inclusion criteria, among which 7468 (71.0%) were peer-reviewed articles. Among these, 4190 publications (56.1%) did not include any data or analytics (comprising expert opinion pieces). Overall, the most represented topics were infectious disease (n = 2326, 22.1%), epidemiology (n = 1802, 17.1%), and global health (n = 1602, 15.2%). The top five publishing countries were China (25.8%), United States (22.3%), United Kingdom (8.8%), Italy (8.1%) and India (3.4%). The dynamic of publication showed that the exponential growth of COVID-19 peer-reviewed articles was mainly driven by publications without original data (mean 261.5 articles ± 51.1 per week) as compared with original articles (mean of 69.3 ± 22.3 articles per week). Original articles including patient data accounted for 713 (9.5%) of peer-reviewed studies. A total of 576 original articles (80.8%) showed intermediate to high risk of bias.

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

Donal Skelly et al.
Nat Commun. 2021 Aug 17;12(1):5061. doi: 10.1038/s41467-021-25167-5. PMID: 34404775
This study analyzed antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020 and showed that neutralization of the variants of concern (VOC) compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. This study concluded that vaccination is required to generate high potency immune responses to protect against these and other emergent variants.

WIT - Picture-a-Scientist Networking Session

WIT - Picture-a-Scientist Networking Session

Friday, August 27, 2021 - 2:00 PM (Local time in South Africa)
Local time (Corresponding local time at your current location)

Moderators:

Elmi Muller, Lydia Cairncross, Keymanthri Moodley


TTS will be exhibiting at ESOT in Milan!

Visit our booth to say hello to Manuela Marchetti, our Director of Meetings!


TTS Masterclasses: Outcome Reporting Series Continues

TTS Members can now register for FREE for the last two Masterclass Series on Transplant Immunology and Outcome Reporting. Members must pre-register to attend the live Masterclasses.

TTS is pleased to announce that the remaining two Masterclass Series (Transplant Immunology Series & Outcome Reporting Series) have been granted European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).

Attendance at the live Masterclasses is mandatory to receive the certificate.

Upcoming Masterclasses


In case you missed it ... SAT Launches Online Training Course

Registration Opens August 27
Course Starts September 2

The Argentine Society of Transplantation (TTS Affiliated Society) has developed an online training course that will assist transplant professionals with the standards, competencies and skills that they require in the field.

The course is offered in spanish only.


Latest Video Posted

August 18, 2021

09:00 (-4 GMT - Montreal time)

View the discussion on solid organ transplant recipient with post-transplant central nervous system (CNS) infection. Our panel will discussed the differential diagnoses and the diagnostic approaches including novel microbiologic tests. Click button below for details.

In the News 


Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada